Market Overview

Mid-Day Market Update: Super Micro Computer Drops Following Weak Guidance; Bio Blast Pharma Shares Surge

Share:

Midway through trading Friday, the Dow traded down 0.04 percent to 17,919.89 while the NASDAQ declined 0.02 percent to 4,944.71. The S&P also fell, dropping 0.08 percent to 2,081.12.

Leading and Lagging Sectors

On Friday, utilities shares gained by 0.43 percent. Meanwhile, top gainers in the sector included York Water Co (NASDAQ: YORW), up 3 percent, and Middlesex Water Company (NASDAQ: MSEX), up 3 percent.

In trading on Friday, energy shares fell by 1.07 percent. Meanwhile, top losers in the sector included Basic Energy Services, Inc (NYSE: BAS), down 6 percent, and GulfMark Offshore, Inc. (NYSE: GLF), down 5 percent.

Top Headline

Citigroup Inc (NYSE: C) reported better-than-expected earnings for the first quarter on Friday.

The bank reported a quarterly profit of $3.5 billion, or $1.10 per share. Its revenue declined 11 percent to $17.56 billion from $19.74 billion. However, analysts were expecting earnings of $1.03 per share on revenue of $17.46 billion.

Equities Trading UP

Great Basin Scientific Inc (NASDAQ: GBSN) shares shot up 82 percent to $4.98. Great Basin Scientific's revenue for the first quarter increased 59.4 percent to $731,422.

Shares of Bio Blast Pharma Ltd (NASDAQ: ORPN) got a boost, shooting up 19 percent to $2.85 after the company announced it will present final data from a Phase 2 clinical study at the American Academy of Neurology (AAN) 2016 Annual Meeting. The company completed a Phase 2 six-month trial of its HOPEMD therapy in patients with oculopharyngeal muscular dystrophy (OPMD).

Infosys Ltd ADR (NYSE: INFY) shares were also up, gaining 8 percent to $19.93 after the company reported its fourth-quarter results. Infosys said it earned $0.23 per share in the fourth quarter on revenue of $2.446 billion. Wall Street analysts were expecting the company to earn $0.23 per share on revenue of $2.43 billion.

Equities Trading DOWN

Sunedison Inc (NYSE: SUNE) shares dropped 33 percent to $0.392. SunEdison and certain of its first and second lien lenders entered into a confidentiality agreement in March in which certain information regarding the company was provided. SunEdison added that its ongoing negotiations with respect to potential financing transactions are still undergoing and there can be no assurance that any agreement will be reached.

Shares of Ixia (NASDAQ: XXIA) were down 18 percent to $10.01 after the company lowered its outlook for the first quarter. Management said it now expects revenue between $108 million and $111 million, down from its previous projection of $121 million to $126 million. Non-GAAP earnings are expected to come in between $0.05 and $0.08 per share, down from a previous guidance of $0.10 to $0.14 per share.

Super Micro Computer, Inc. (NASDAQ: SMCI) was down, falling around 16 percent to $28.02 after the company issued a weak forecast for the third quarter.

Commodities

In commodity news, oil traded down 3.57 percent to $40.02 while gold traded up 0.40 percent to $1,231.40.

Silver traded up 0.14 percent Friday to $16.20, while copper fell 1.29 percent to $2.14.

Eurozone

European shares were lower today. The eurozone's STOXX 600 declined 0.40 percent, the Spanish Ibex Index fell 0.06 percent, while Italy's FTSE MIB Index slipped 0.35 percent. Meanwhile, the German DAX dropped 0.34 percent, and the French CAC 40 slipped 0.36 percent, while U.K. shares fell 0.30 percent.

Economics

The Empire State manufacturing index increased to 9.6 for April, compared to 0.6 in March

U.S. industrial production declined 0.50 percent for March, versus economists' expectations for a 0.10 percent drop.

The University of Michigan's consumer sentiment index slipped to 89.70 in April, versus a prior reading of 91.00. Economists were expecting a reading of 92.00.

Posted-In: Earnings News Guidance Eurozone Commodities Global Intraday Update Markets

 

Related Articles (BAS + C)

View Comments and Join the Discussion!

Ocera Therapeutics To Present Two Preclinical Studies At The International Liver Congress

Report: Valeant Has Tapped Investment Bankers To Help Review Strategic Options